Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
Insulin-like growth factor I (IGF-I) has many potential therapeutic uses because of its varied effects--growth promotion, insulin-like influence on glucose metabolism, and neuroprotection resulting from cell-proliferative and antiapoptotic properties--but they have not been investigated systematically in clinical situations. The growth-promoting effect of recombinant human IGF-I (rhIGF-I) in the extensively studied growth hormone insensitivity syndrome (GHIS; Laron syndrome) signifies an endocrine role for the GH-IGF system. The metabolism of (adult) patients with severe insulin resistance is improved by rhIGF-I, which--together with insulin therapy--also improves metabolic control in type 1 and 2 diabetes. Further studies on IGF-I metabolic effects and growing understanding of the IGF-I-IGF-binding protein system could open new therapeutic avenues.
Ranke
Michael B
MB
Paediatric Endocrinology Section, University Children's Hospital, Hoppe-Seyler-Strasse 1, D-72076 Tübingen, Germany. michael.ranke@med.uni-tuebingen.de
D000273:Adipose Tissue / Q000502:physiology; D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000502:physiology; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D007334:Insulin-Like Growth Factor I / Q000009:adverse effects / Q000627:therapeutic use*
D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I